Shimojani
Shimojani LLC is a biotech company focused on developing therapies to reduce hemorrhage risk in acute ischemic stroke patients. They have licensed a novel invention from Niigata University that targets a key pathway involved in stroke severity, aiming to advance this work into clinical trials to improve survival and quality of life for stroke victims.
Industries
Shimojani
San Francisco, California, United States, North America
Products
Licensed therapeutic program to reduce hemorrhagic conversion in acute ischemic stroke
An academic-origin therapeutic program licensed for development and commercialization aimed at reducing hemorrhagic conversion in acute ischemic stroke patients, including those treated with thrombolytic agents; program is in preclinical and IND-enabling development.
Licensed therapeutic program to reduce hemorrhagic conversion in acute ischemic stroke
An academic-origin therapeutic program licensed for development and commercialization aimed at reducing hemorrhagic conversion in acute ischemic stroke patients, including those treated with thrombolytic agents; program is in preclinical and IND-enabling development.
Services
Preclinical development and translational research for stroke therapeutics
Validation and advancement of therapeutic candidates from animal models toward IND-enabling studies, including biomarker analysis and coordination with clinical experts.
Preclinical development and translational research for stroke therapeutics
Validation and advancement of therapeutic candidates from animal models toward IND-enabling studies, including biomarker analysis and coordination with clinical experts.
Expertise Areas
- Acute ischemic stroke therapeutics
- Preclinical model development and validation
- IND-enabling development and regulatory strategy
- Biomarker-driven translational validation
Key Technologies
- Rodent ischemic stroke models
- Signal transduction pathway analysis
- Biomarker assays for pathway activation
- Small-molecule drug evaluation